ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company is also developing Avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and in atypical hemolytic uremic syndrome (aHUS). In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy (DN) and is being developed for patients with focal segmental glomerulosclerosis (FSGS). Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CCXI
CUSIP16383L10
Phone650-210-2900
Debt
Debt-to-Equity Ratio0.18
Current Ratio1.95
Quick Ratio1.95
Price-To-Earnings
Trailing P/E Ratio43.24
Forward P/E Ratio-15.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$82.50 million
Price / Sales7.42
Cash Flow$0.3723 per share
Price / Cash33.47
Book Value$1.63 per share
Price / Book7.64
Profitability
EPS (Most Recent Fiscal Year)$0.36
Net IncomeN/A
Net MarginsN/A
Return on Equity31.56%
Return on Assets9.03%
Miscellaneous
Employees66
Outstanding Shares49,150,000
Market Cap$616.34
ChemoCentryx (NASDAQ:CCXI) Frequently Asked Questions
What is ChemoCentryx's stock symbol?
ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."
How were ChemoCentryx's earnings last quarter?
ChemoCentryx Inc (NASDAQ:CCXI) announced its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. The biopharmaceutical company earned $9.55 million during the quarter, compared to analysts' expectations of $9.10 million. View ChemoCentryx's Earnings History.
What price target have analysts set for CCXI?
5 Wall Street analysts have issued 12 month target prices for ChemoCentryx's shares. Their predictions range from $16.00 to $20.00. On average, they expect ChemoCentryx's share price to reach $17.75 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Ratings for ChemoCentryx.
What is the consensus analysts' recommendation for ChemoCentryx?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
Who are some of ChemoCentryx's key competitors?
Some companies that are related to ChemoCentryx include Clovis Oncology (CLVS), Endo International (ENDP), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), ACADIA Pharmaceuticals (ACAD), TESARO (TSRO), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Akorn (AKRX), Myokardia (MYOK), Prestige Brands (PBH), Puma Biotechnology (PBYI) and Insmed (INSM).
Who are ChemoCentryx's key executives?
ChemoCentryx's management team includes the folowing people:
- Dr. Thomas J. Schall Ph.D., Founder, Pres, CEO & Chairman (Age 59)
- Ms. Susan M. Kanaya, Exec. VP, Chief Financial & Admin. Officer and Sec. (Age 55)
- Mr. William C. Fairey Jr., Exec. VP & COO (Age 53)
- Dr. Rajinder Singh, Sr. VP of Research (Age 51)
- Dr. Jan L. Hillson M.D., Sr. VP of Drug Devel. (Age 65)
Has ChemoCentryx been receiving favorable news coverage?
News headlines about CCXI stock have trended somewhat positive on Thursday, Accern reports. The research group scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ChemoCentryx earned a news sentiment score of 0.13 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
Who are ChemoCentryx's major shareholders?
ChemoCentryx's stock is owned by many different of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.21%). Company insiders that own ChemoCentryx stock include Markus J Cappel, Petrus Bekker, Roger C Lucas, Susan M Kanaya and Thomas J Schall. View Institutional Ownership Trends for ChemoCentryx.
Which institutional investors are buying ChemoCentryx stock?
How do I buy shares of ChemoCentryx?
Shares of CCXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChemoCentryx's stock price today?
One share of CCXI stock can currently be purchased for approximately $12.46.
How big of a company is ChemoCentryx?
ChemoCentryx has a market capitalization of $616.34 million and generates $82.50 million in revenue each year. ChemoCentryx employs 66 workers across the globe.
How can I contact ChemoCentryx?
ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The biopharmaceutical company can be reached via phone at 650-210-2900 or via email at [email protected]
MarketBeat Community Rating for ChemoCentryx (NASDAQ CCXI)
MarketBeat's community ratings are surveys of what our community members think about ChemoCentryx and other stocks. Vote "Outperform" if you believe CCXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CCXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
